Rosuvastatin use is contraindicated during breastfeeding [see Contraindications (4)]. Limited data indicate that rosuvastatin is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for serious adverse reactions in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with rosuvastatin.
Rosuvastatin may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with rosuvastatin.
Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Of the 10,275 patients in clinical studies with rosuvastatin, 3,159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Elderly patients are at higher risk of myopathy and rosuvastatin should be prescribed with caution in the elderly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr ≥30 mL/min/1.73 m2). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) who are not receiving hemodialysis and dose adjustment is required [see Dosage and Administration (2.5), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Rosuvastatin is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels. Chronic alcohol liver disease is known to increase rosuvastatin exposure; rosuvastatin should be used with caution in these patients [see Contraindications(4), Warning and Precautions (5.2) and Clinical Pharmacology (12.3)].
Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects when compared with Caucasian controls. Rosuvastatin dosage should be adjusted in Asian patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis does not significantly enhance clearance of rosuvastatin.
The chemical name for rosuvastatin calcium USP is bis[(E)-7-[4- (4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S) -3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:
The empirical formula for rosuvastatin calcium USP is (C22 H27 FN3 O6 S)2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium USP is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0.
Rosuvastatin Calcium USP for oral administration contain 5, 10, 20, or 40 mg of rosuvastatin and the following inactive ingredients: Each tablet contains: crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide and triacetin. Additionally, the 5 mg tablet contains ferric oxide yellow and the 10 mg, 20 mg and 40 mg tablets contain ferric oxide red.
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. In vivo studies in animals, and in vitro studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for cholesterol lowering. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both Cmax and AUC increased in approximate proportion to rosuvastatin dose. The absolute bioavailability of rosuvastatin is approximately 20%.
Administration of rosuvastatin with food did not affect the AUC of rosuvastatin.
The AUC of rosuvastatin does not differ following evening or morning drug administration.
Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.
Rosuvastatin is primarily eliminated by excretion in the feces. The elimination half-life of rosuvastatin is approximately 19 hours.
Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.
Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.
Racial or Ethnic Groups
A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and Cmax ) in Asian subjects when compared with a Caucasian control group.
Male and Female Patients
There were no differences in plasma concentrations of rosuvastatin between men and women.
Pediatric use information for patients ages 8 to less than 10 years is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age ≥65 years).
Patients with Renal Impairment
Mild to moderate renal impairment (CLcr ≥30 mL/min/1.73 m2) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3- fold) in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not receiving hemodialysis compared with healthy subjects (CLcr >80 mL/min/1.73 m2).
Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.
Patients with Hepatic Impairment
In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.
In patients with Child-Pugh A disease, Cmax and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh B disease, Cmax and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.
Drug Interactions Studies
Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.
Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of rosuvastatin with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma concentrations [see Dosage and Administration(2.4) and Drug Interactions (7.1, 7.3)]
1 Single dose unless otherwise noted.
2 Clinically significant [seeDosage and Administration (2 ) and Warnings and Precautions(5) ]
3 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11 fold increase in exposure)
|Coadministered drug and dosing regimen||Rosuvastatin|
|Mean Ratio (ratio with/without coadministered drug) No Effect = 1.0|
|Dose (mg)1||Change in AUC||Change in Cmax|
|Cyclosporine – stable dose required (75 mg to 200 mg BID)||10 mg QD for 10 days||7.12||112|
|Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days||10 mg||3.12||72|
|Simeprevir 150 mg QD, 7 days||10 mg, single dose||2.82 (2.3 to 3.4)3||3.22 (2.6 to 3.9)3|
|Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days||20 mg QD for 7 days||2.12 (1.7 to 2.6)3||52 (3.4 to 6.4)3|
|Gemfibrozil 600 mg BID for 7 days||80 mg||1.92 (1.6 to 2.2)3||2.22 (1.8 to 2.7)3|
|Eltrombopag 75 mg QD, 5 days||10 mg||1.6 (1.4 to 1.7)3||2 (1.8 to 2.3)3|
|Darunavir 600 mg/ritonavir 100 mg BID, 7 days||10 mg QD for 7 days||1.5 (1.0 to 2.1)3||2.4 (1.6 to 3.6)3|
|Tipranavir/ritonavir combination 500 mg/200mg BID for 11 days||10 mg||1.4 (1.2 to 1.6)3||2.2 (1.8 to 2.7)3|
|Dronedarone 400 mg BID||10 mg||1.4|
|Itraconazole 200 mg QD, 5 days||10 mg or 80 mg||1.4 (1.2 to 1.6)3 1.3 (1.1 to 1.4)3||1.4 (1.2 to 1.5)3 1.2 (0.9 to 1.4)3|
|Ezetimibe 10 mg QD, 14 days||10 mg QD for 14 days||1.2 (0.9 to 1.6)3||1.2 (0.8 to 1.6)3|
|Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days||10 mg||1.1||1.5|
|Fenofibrate 67 mg TID for 7 days||10 mg||↔||1.2 (1.1 to 1.3)3|
|Rifampicin 450 mg QD, 7 days||20 mg||↔|
|Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart||40 mg 40 mg||0.52 (0.4 to 0.5)3 0.8 (0.7 to 0.9)3||0.52 (0.4 to 0.6)3 0.8 (0.7 to 1.0)3|
|Ketoconazole 200 mg BID for 7 days||80 mg||1.0 (0.8 to 1.2)3||1.0 (0.7 to 1.3)3|
|Fluconazole 200 mg QD for 11 days||80 mg||1.1 (1.0 to 1.3)3||1.1 (0.9 to 1.4)3|
|Erythromycin 500 mg QID for 7 days||80 mg||0.8 (0.7 to 0.9)3||0.7 (0.5 to 0.9)3|
EE = ethinyl estradiol, NG = norgestrel
1 Clinically significant pharmacodynamic effects [seeWarnings and Precautions (5.3) ]
2 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure)
|Rosuvastatin Dosage Regimen||Coadministered Drug|
|Mean Ratio (ratio with/without coadministered drug) No Effect = 1.0|
|Name and Dose||Change in AUC||Change in Cmax|
|40 mg QD for 10 days||Warfarin 1 25 mg single dose||R-Warfarin 1.0 (1.0 to 1.1)2 S-Warfarin 1.1 (1.0 to 1.1)2||R-Warfarin 1.0 (0.9 to 1.0)2 S-Warfarin 1.0 (0.9 to1.1)2|
|40 mg QD for 12 days||Digoxin 0.5 mg single dose||1.0 (0.9 to 1.2)2||1.0 (0.9 to 1.2)2|
|40 mg QD for 28 days||Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days||EE 1.3 (1.2 to 1.3)2 NG 1.3 (1.3 to 1.4)2||EE 1.3 (1.2 to 1.3)2 NG 1.2 (1.1 to 1.3)2|
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.